Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker CVSA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Manjunath Gangadharan VP, Chief Accounting Officer | CVSA Covista Inc. | Sale | 1,802 | $137.18 | $247.2K Sale | Form 4 ↗ |
| Aug 11, 2026 | Stephen W. Beard Chairman & CEO | CVSA Covista Inc. | Sale | 3,545 | $130.35 | $462.1K Sale | Form 4 ↗ |
| Aug 7, 2026 | Robert J. Phelan Chief Financial Officer | CVSA Covista Inc. | Sale | 2,186 | $135.15 | $295.4K Sale | Form 4 ↗ |
| Aug 7, 2026 | Douglas G. Beck SVP, GC, Corp. Sec & ISS | CVSA Covista Inc. | Sale | 4,526 | $135.81 | $614.7K Sale | Form 4 ↗ |
| Jul 13, 2026 | Stephen W. Beard Chairman & CEO | CVSA Covista Inc. | Sale | 5,291 | $132.75 | $702.4K Sale | Form 4 ↗ |
| Jul 8, 2026 | Robert J. Phelan Chief Financial Officer | CVSA Covista Inc. | Sale | 2,414 | $135.39 | $326.8K Sale | Form 4 ↗ |
| Jul 8, 2026 | Douglas G. Beck SVP, GC, Corp. Sec & ISS | CVSA Covista Inc. | Sale | 2,439 | $135.34 | $330.1K Sale | Form 4 ↗ |
| Jul 7, 2026 | Robert J. Phelan Chief Financial Officer | CVSA Covista Inc. | Sale | 2,900 | $135.41 | $392.7K Sale | Form 4 ↗ |
| Jul 7, 2026 | Douglas G. Beck SVP, GC, Corp. Sec & ISS | CVSA Covista Inc. | Sale | 2,650 | $135.40 | $358.8K Sale | Form 4 ↗ |
| Jun 11, 2026 | Stephen W. Beard Chairman & CEO | CVSA Covista Inc. | Sale | 2,529 | $130.78 | $330.7K Sale | Form 4 ↗ |
| Jun 10, 2026 | Stephen W. Beard Chairman & CEO | CVSA Covista Inc. | Sale | 2,762 | $130.14 | $359.4K Sale | Form 4 ↗ |
| May 8, 2026 | Robert J. Phelan Chief Financial Officer | CVSA Covista Inc. | Sale | 10,000 | $126.21 | $1.3M Sale | Form 4 ↗ |
| May 8, 2026 | Douglas G. Beck SVP, GC, Corp. Sec & ISS | CVSA Covista Inc. | Sale | 9,615 | $127.03 | $1.2M Sale | Form 4 ↗ |
| May 8, 2026 | Karen Sue Cox President, Chamberlain Univ. | CVSA Covista Inc. | Sale | 2,000 | $124.50 | $249.0K Sale | Form 4 ↗ |
| May 8, 2026 | Stephen W. Beard Chairman & CEO | CVSA Covista Inc. | Sale | 15,874 | $131.25 | $2.1M Sale | Form 4 ↗ |
| Mar 11, 2026 | Michael W. Malafronte Director | CVSA Covista Inc. | Buy | 8,890 | $100.94 | $897.4K Buy | Form 4 ↗ |
| Mar 10, 2026 | Michael W. Malafronte Director | CVSA Covista Inc. | Buy | 15,305 | $100.86 | $1.5M Buy | Form 4 ↗ |
| Mar 10, 2026 | Michael W. Malafronte Director | CVSA Covista Inc. | Buy | 11,841 | $100.86 | $1.2M Buy | Form 4 ↗ |
| Mar 3, 2026 | Michael W. Malafronte Director | CVSA Covista Inc. | Buy | 1,200 | $97.97 | $117.6K Buy | Form 4 ↗ |
| Nov 5, 2025 | Kenneth J. Phelan Director | ATGE Covista Inc. | Buy | 508 | $98.29 | $49.9K Buy | Form 4 ↗ |
| Nov 4, 2025 | Michael W. Malafronte Director | ATGE Covista Inc. | Buy | 1,000 | $91.85 | $91.8K Buy | Form 4 ↗ |
| Aug 28, 2025 | Lisa W. Wardell Director | ATGE Covista Inc. | Sale | 25,477 | $132.38 | $3.4M Sale | Form 4 ↗ |
| Aug 27, 2025 | Lisa W. Wardell Director | ATGE Covista Inc. | Sale | 18,392 | $135.22 | $2.5M Sale | Form 4 ↗ |
| Aug 27, 2025 | Manjunath Gangadharan VP, Chief Accounting Officer | ATGE Covista Inc. | Sale | 944 | $135.67 | $128.1K Sale | Form 4 ↗ |
| Aug 21, 2025 | Lisa W. Wardell Director | ATGE Covista Inc. | Sale | 12,900 | $132.90 | $1.7M Sale | Form 4 ↗ |
| Jun 5, 2025 | William W. Burke Director | ATGE Covista Inc. | Sale | 2,291 | $128.35 | $294.0K Sale | Form 4 ↗ |
| May 21, 2025 | Manjunath Gangadharan VP, Chief Accounting Officer | ATGE Covista Inc. | Sale | 966 | $131.66 | $127.2K Sale | Form 4 ↗ |
| Mar 7, 2025 | Michael W. Malafronte Director | ATGE Covista Inc. | Buy | 1,000 | $87.21 | $87.2K Buy | Form 4 ↗ |
| Feb 21, 2025 | Donna J. Hrinak Director | ATGE Covista Inc. | Sale | 915 | $97.92 | $89.6K Sale | Form 4 ↗ |
| Feb 14, 2025 | Donna J. Hrinak Director | ATGE Covista Inc. | Sale | 4,812 | $103.26 | $496.9K Sale | Form 4 ↗ |
| Feb 6, 2025 | Donna J. Hrinak Director | ATGE Covista Inc. | Sale | 4,685 | $108.68 | $509.2K Sale | Form 4 ↗ |
| Feb 6, 2025 | Michael Betz Pres. Walden University & CDO | ATGE Covista Inc. | Sale | 3,500 | $108.57 | $380.0K Sale | Form 4 ↗ |
| Nov 29, 2024 | William W. Burke Director | ATGE Covista Inc. | Sale | 4,000 | $90.39 | $361.6K Sale | Form 4 ↗ |
33 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances